The evidence with the title 'Genentech Her2 Story ' says Though the battle is far from over, the progress they have made Not only  ... “ it was frustrating , ” says Dennis Slamon, M.D., Ph.D., director of clinical and  ... It appeared that having too many HER2 receptors did n't just contribute to  ... Startup would invest in a development program in such an uncharted area .  ... .. 40.8 months ) .
